BNOX
NASDAQBionomics Limited
Latest news
25 items- SECAmendment: SEC Form S-3/A filed by Bionomics LimitedS-3/A - Neuphoria Therapeutics Inc. (0001191070) (Filer)
- SECSEC Form EFFECT filed by Bionomics LimitedEFFECT - Neuphoria Therapeutics Inc. (0001191070) (Filer)
- SECSEC Form EFFECT filed by Bionomics LimitedEFFECT - Neuphoria Therapeutics Inc. (0001191070) (Filer)
- SECBionomics Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Changes in Control of Registrant, Leadership Update, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Financial Statements and Exhibits8-K - BIONOMICS LIMITED/FI (0001191070) (Filer)
- SECSEC Form POS AM filed by Bionomics LimitedPOS AM - BIONOMICS LIMITED/FI (0001191070) (Filer)
- SECSEC Form POS AM filed by Bionomics LimitedPOS AM - BIONOMICS LIMITED/FI (0001191070) (Filer)
- SECSEC Form 15-12G filed by Bionomics Limited15-12G - BIONOMICS LIMITED/FI (0001191070) (Filer)
- SECBionomics Limited filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BIONOMICS LIMITED/FI (0001191070) (Filer)
- PRBionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-DomiciliationADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company) is pleased to announce that the Supreme Court of New South Wales, Australia ("Court") has today made orders approving the scheme of arrangement in relation to the Company's proposed re-domiciliation from Australia to the United States ("Scheme"), under which Neuphoria Therapeutics Inc., a Delaware corporation ("Neuphoria"), will become the ultimate parent company of Bionomics Limited following the implementation of the Scheme. A copy of the Court's orders with respect to the Scheme was lodged with the Australian Securities & Investments Commission following t
- SECBionomics Limited filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - BIONOMICS LIMITED/FI (0001191070) (Filer)
- PRResults of Scheme MeetingADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) ("Bionomics" or the "Company") is pleased to provide the following update on the status of its proposed re-domiciliation from Australia to the United States. Bionomics shareholders have today approved, by the requisite majority, the proposed Scheme of Arrangement in relation to the Company's proposed re-domiciliation from Australia to the United States, under which Neuphoria Therapeutics Inc., a Delaware corporation ("Neuphoria"), will become the ultimate parent company of Bionomics Limited following the implementation of the Scheme of Arrangement. Voting Results In summary: 96%
- PRBionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM EvidenceBNC210 improved PTSD symptom severity at Week 12 with efficacy observed as early as Week 4Company plans to initiate a Phase 3 study of BNC210 in PTSD in H2 2025 ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that the positive results from its Phase 2 ATTUNE study have been published in the NEJM Evidence. The data were also presented yesterday at the 63ʳᵈ Annual Meeting of the
- PRBionomics to Present at the 2024 American College of Neuropsychopharmacology Annual MeetingADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be giving oral presentation on the results of the Phase 2 ATTUNE trial of BNC210 in post-traumatic stress disorder in the inaugural "Promising Targets" session at the 63ʳᵈ Annual Meeting of the American College of Neuropsychopharmacology (ACNP) being held December 8-11, 2024 in Phoenix, AZ. Oral Presentation Details:
- PRBionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United StatesADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, is reminding Shareholders to cast their vote in favor of the Scheme Implementation Agreement to re-domicile Bionomics from Australia to the U.S. "The re-domiciliation of Bionomics through the Scheme is key for our ability to execute our strategic vision and set the Company for success. I'd like to highlight that voting in favor of the Scheme was
- SECAmendment: SEC Form S-3/A filed by Bionomics LimitedS-3/A - BIONOMICS LIMITED/FI (0001191070) (Filer)
- SECBionomics Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - BIONOMICS LIMITED/FI (0001191070) (Filer)
- SECSEC Form S-3 filed by Bionomics LimitedS-3 - BIONOMICS LIMITED/FI (0001191070) (Filer)
- SECSEC Form 10-Q filed by Bionomics Limited10-Q - BIONOMICS LIMITED/FI (0001191070) (Filer)
- 13D/GSEC Form SC 13G filed by Bionomics LimitedSC 13G - BIONOMICS LIMITED/FI (0001191070) (Subject)
- 13D/GAmendment: SEC Form SC 13G/A filed by Bionomics LimitedSC 13G/A - BIONOMICS LIMITED/FI (0001191070) (Subject)
- SECSEC Form DEFA14A filed by Bionomics LimitedDEFA14A - BIONOMICS LIMITED/FI (0001191070) (Filer)
- SECSEC Form DEF 14A filed by Bionomics LimitedDEF 14A - BIONOMICS LIMITED/FI (0001191070) (Filer)
- SECBionomics Limited filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BIONOMICS LIMITED/FI (0001191070) (Filer)
- PRBionomics Provides an Update on Re-domiciliation via Scheme of ArrangementADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today provides an update to the proposed re-domiciliation of Bionomics to the United States by way of scheme of arrangement between Bionomics and its Shareholders ("Scheme") as announced on 1 October 2024. Shareholders of Bionomics will receive a proportionate number of shares of common stock in Neuphoria Therapeutics Inc. ("Neuphoria"), a new
- PRBionomics to Present at the 2024 CNS SummitADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be participating and presenting at the 15th CNS Summit being held November 10-13, 2024 at the Encore Boston Hotel in Boston, MA. Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics, will deliver a company presentation during the Neuroscience Spotlight session taking place on Tuesday, November 12
BNOX FAQ
7 questionsWhat does Bionomics Limited do?
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a...Where does BNOX stock trade?
Bionomics Limited (BNOX) is listed on NASDAQ.What sector and industry is BNOX in?
Bionomics Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Bionomics Limited go public?
Bionomics Limited (BNOX) completed its IPO in 2021.What are analysts saying about BNOX?
Bionomics Limited has had 6 recent analyst actions on file. The most recent action was from Maxim Group: Buy with a $1000.00 price target on 2023-09-28. Recent price targets range from $800.00 to $2100.00.What companies are similar to BNOX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BNOX side-by-side with any of them on Quantisnow.How can I track BNOX on Quantisnow?
Quantisnow aggregates Bionomics Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BNOX to receive live email and push alerts on every new disclosure.